Exo Imaging Exit Candidate

Employees 100+
Primary contact

🏦 Potential exit path: SPAC, IPO, M&A
Exo (pronounced "Echo") is pioneering a high-performance handheld ultrasound platform and AI for imaging and therapeutic applications. The Exo ultrasound platform combines advances in nano-materials, novel sensor technologies, advanced signal processing and computation with the economies of scale of semiconductor manufacturing to dramatically reduce the cost of imaging. By delivering easy-to-use, high quality medical imaging - Exo will empower healthcare professionals to make critical, real-time decisions that improve patient outcomes — bringing diagnostic-grade medical imaging to the pocket of every caregiver and clinician worldwide.
Employees 100+
Primary contact

Funding πŸ’°

Total $307.6M
Last round πŸ”— $220M
Series C
August 2, 2021.
Select investors RA Capital Management, Action Potential Venture Capital, Applied Ventures, BlackRock, Bold Capital Partners, Creative Ventures, Intel Capital, OSF Ventures, Pura Vida Investments

Key people πŸ§‘β€πŸ€β€πŸ§‘

Highlights ⭐

  • Exo's team has experience in developing and delivering global innovation in medical technology - Eric King & Christian Buerger from Intel Capital πŸ”—
  • Exo's piezoelectric transducer is a differentiator that allows the company to have the ability to deliver low-cost, high-quality imaging to new and expanding audiences - Eric King & Christian Buerger from Intel Capital πŸ”—
  • The ultrasound market is undergoing a fundamental transformation toward more distributed use and Exo is positioned to become a market leader as a result - RA Capital Management principal Zach Scheiner, Ph.D πŸ”—
  • The company has support from major healthcare & pharma firms such as GSK (through Action Potential Venture Capital) and OSF HealthCare (through OSF Ventures) πŸ”—
  • And also from strategic supply chain-focused investors such as Intel Capital, TDK Ventures, Compal and Applied Ventures πŸ”—
  • Similar companies: Butterfly Network
Last update: September 6, 2021